E P E N D Y M O M A 2 0 2 4
Expanding the Frontiers of Personalized Medicine: PNOC027 and its Application to Relapsed Ependymoma
approach incorporates a specialized drug screen. This screen tests tumor cells against hundreds of drugs to identify which are most effective in killing them. A molecular tumor board then reviews these results to develop a combination therapy plan, typically involving three to four drugs. This method not only tailors the treatment to the unique characteristics of each tumor but also reduces the risk of administering ineffective or overly toxic therapies
Expansion to Ependymoma: Addressing a Critical Need
Initially focused on medulloblastoma, the PNOC027 clinical trial is now expanding to include ependymoma, a complex pediatric brain cancer lacking effective treatments for relapse cases. This strategic move applies our precision medicine approach to a broader spectrum of pediatric brain cancers Ependymoma's few mutations and the availability of tissue from surgical re-resections make it an ideal candidate for this trial Using 'off the shelf‘ drugs, already approved for other uses, enhances the efficiency of our treatment process, aiming to provide novel, targeted therapies for young patients with limited options.
cancer patients have seen the dividends of investments in precision medicine, and we want to give those same opportunities to pediatric brain cancer patients.
This initiative promises not just hope for today's young patients but also a legacy of improved outcomes and innovative care for future generations.
